![]() |
市場調查報告書
商品編碼
1403433
2030 年肺計量計市場預測:按產品、技術、應用、最終用戶和地區進行的全球分析Spirometers Market Forecasts to 2030 - Global Analysis By Product, By Technology, Application (Chronic Obstructive Pulmonary Disease, Asthma and Other Applications), End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球肺計量計市場規模為 11.552 億美元,預計到 2030 年將達到 27.363 億美元,預測期內複合年成長率為 13.1%。
肺計量計是醫療設備。這些設備測量重要的呼吸參數,例如肺活量、氣流和呼吸肌肉效率。透過分析呼吸過程中空氣運動的體積和速度,肺計量計可以幫助診斷和監測氣喘、慢性阻塞性肺病(COPD) 和其他呼吸系統疾病,指導治療並評估肺功能。
根據國家心肺血液研究所 2022 年 3 月發表的一篇論文,慢性阻塞性肺病是美國的首要死因,約 1,600 萬美國人罹患。
全球氣喘、慢性阻塞性肺病和肺纖維化等呼吸系統疾病的盛行率不斷上升,增加了對評估肺功能的診斷工具的需求。肺計量計在診斷這些疾病、監測疾病進展和評估治療效果方面發揮著至關重要的作用。隨著人們越來越重視呼吸系統疾病的早期檢測和管理,對肺活量測定設備的需求持續成長,推動市場擴張以滿足不斷成長的醫療保健需求。
在某些社區和醫療機構中,人們對呼吸健康評估的重要性以及肺活量測定法測試的好處認知不足。此外,獲得醫療保健設施的差異限制了肺活量計在偏遠和服務欠缺地區的使用。醫療保健專業人員培訓不足也阻礙了採用。缺乏意識和有限的可及性阻礙了肺活量測定工具的普及,限制了其使用,並影響了市場成長。
人們對家庭醫療保健的日益青睞為肺計量計市場帶來了機會。隨著患者尋求方便的監測選擇,攜帶式肺計量計透過允許在家庭環境中進行呼吸評估來應對這一趨勢。這些設備可以讓慢性呼吸道疾病患者定期監測肺功能,有助於及時介入並減少就診次數。此外,向居家照護的轉變,符合患者對獨立性和便利性的偏好,正在推動對攜帶式肺活量測定解決方案的需求,提供傳統醫療機構之外的呼吸監測選項,這將擴大市場。
當肺活量測定設備與數位系統連接並整合以進行資料儲存和分析時,潛在違規、詐欺的存取和資料濫用的風險就會增加。在肺活量測定期間收集的患者健康資訊需要受到保護以確保機密性。如果無法解決這些問題,就會削弱患者的信任,阻礙採用,並受到監管審查。
在 COVID-19 爆發期間,肺計量計面臨挑戰和適應。最初,人們對肺活量測定過程中氣溶膠的產生產生了擔憂,由於感染風險而影響了其使用。然而,隨著了解的增加,已經建立了協議來確保安全的肺活量測定性能,特別是對於關鍵的呼吸評估。此外,疫情加速了遠端監控和遠端醫療解決方案的開發,並促進了肺計量計與虛擬醫療機構的整合。
在預測期內,流量測量領域由於其在評估呼吸功能方面的基本作用,預計將主導肺計量計市場。流量測量提供有關吸氣和呼氣期間空氣移動速度的重要資料,可用於診斷和監測呼吸系統疾病。此外,流量測量的準確性和靈敏度極大地有助於準確的呼吸評估,因此是肺計量計市場中該細分市場預期主導地位的關鍵促進因素。
在預測期內,醫院部門可能會顯著成長。該醫院仍然是綜合醫療保健服務的主要中心,包括呼吸系統診斷和治療。隨著呼吸系統疾病盛行率的上升,醫院對先進肺活量測定設備的需求不斷增加。此外,對呼吸系統疾病的早期檢測和管理的日益關注增加了醫院環境中對準確診斷工具的需求。此外,技術進步以及肺活量計與醫院資訊系統的整合進一步推動了這一領域的成長。
由於先進的醫療基礎設施、高昂的醫療成本以及對呼吸健康的高度重視,北美在肺計量計市場中佔據了最大的市場佔有率。此外,意識的提高、有利的報銷政策以及肺活量測定設備的技術進步也促進了市場的成長。此外,北美呼吸系統疾病的高盛行率和對醫療保健創新的積極承諾,使該地區成為關鍵的市場領導者,在肺活量測定解決方案的採用和實施中佔有很大佔有率。
由於呼吸系統疾病盛行率上升和老年人口增加,預計亞太地區肺計量計市場將強勁成長。此外,醫療支出的增加、醫療基礎設施的改善以及呼吸健康意識的提高正在進一步推動市場。此外,技術進步、攜帶式和負擔得起的肺活量測定設備的採用以及農村地區醫療保健服務的擴大正在推動亞太地區的市場成長。
According to Stratistics MRC, the Global Spirometers Market is accounted for $1155.2 million in 2023 and is expected to reach $2736.3 million by 2030 growing at a CAGR of 13.1% during the forecast period. Spirometers are medical devices used to measure lung function by assessing the volume of air inhaled or exhaled. These instruments gauge vital respiratory parameters, including lung capacity, airflow and the efficiency of respiratory muscles. By analyzing the volume and speed of air movement during breathing maneuvers, spirometers aid in diagnosing and monitoring conditions like asthma, chronic obstructive pulmonary disease (COPD) and other respiratory disorders, guiding treatment and evaluating pulmonary function.
According to an article published by the National Heart, Lung, and Blood Institute in March 2022, COPD is the leading cause of death in the U.S., affecting about 16 million Americans.
Owing to the increasing prevalence of respiratory diseases like asthma, COPD, and pulmonary fibrosis worldwide, there's a heightened demand for diagnostic tools to assess lung function. Spirometers play a pivotal role in diagnosing these ailments, monitoring disease progression, and evaluating treatment efficacy. With a rising emphasis on early detection and management of respiratory disorders, the demand for spirometry devices continues to grow, driving market expansion to cater to the escalating healthcare needs.
In certain regions or healthcare settings, there's inadequate awareness regarding the importance of respiratory health assessment and the benefits of spirometry testing. Additionally, disparities in access to healthcare facilities restrict the availability of spirometers in remote or underserved areas. Insufficient training among healthcare professionals further impedes adoption. This lack of awareness and limited accessibility hinders widespread adoption of spirometry tools, constraining their usage and impacting market growth.
The increasing inclination towards home healthcare presents an opportunity in the spirometers market. As patients seek convenient monitoring options, portable spirometers cater to this trend by enabling respiratory assessments in home settings. These devices allow individuals with chronic respiratory conditions to regularly monitor lung function, facilitating timely intervention and reducing hospital visits. Moreover, the shift towards home-based care aligns with patient preferences for independence and convenience, driving the demand for portable spirometry solutions and expanding the market by offering accessible respiratory monitoring options outside traditional healthcare facilities.
When spirometry devices are connected and integrated with digital systems for data storage and analysis, there's a heightened risk of potential breaches, unauthorized access or data misuse. Patient health information collected during spirometry tests requires protection to ensure confidentiality. Failure to address these concerns can erode patient trust, hinder adoption, and lead to regulatory scrutiny.
During the COVID-19 pandemic, spirometers faced challenges and adaptations. Initially, concerns arose regarding aerosol generation during spirometry tests, impacting their use due to infection risks. However, as understanding evolved, protocols were established to ensure safe spirometry practices, especially for essential respiratory assessments. Additionally, the pandemic accelerated the development of remote monitoring and telemedicine solutions, fostering the integration of spirometers into virtual healthcare setups, allowing continued respiratory monitoring and management while minimizing in-person contact and enhancing remote patient care.
Over the forecast period, the flow measurement segment is anticipated to dominate the spirometers market, attributed to its fundamental role in assessing respiratory function. Flow measurements provide crucial data on the rate of air movement during inhalation and exhalation, aiding in the diagnosis and monitoring of respiratory conditions. Moreover, the precision and sensitivity of flow measurements contribute significantly to accurate respiratory assessments, making them a key driver for the segment's anticipated dominance in the spirometers market.
During the forecast period, the hospitals segment is poised to witness significant growth. Hospitals remain the primary centers for comprehensive healthcare services, including respiratory diagnostics and treatment. With a rising incidence of respiratory ailments, hospitals demand for advanced spirometry equipment is escalating. Additionally, the increasing focus on early detection and management of respiratory diseases augments the need for accurate diagnostic tools in hospital settings. Moreover, technological advancements and the integration of spirometers into hospital information systems further drive the growth of this segment.
North America is set to secure the largest market share in the spirometers market owing to its advanced healthcare infrastructure, high healthcare expenditure and robust focus on respiratory health. Additionally, increased awareness, favorable reimbursement policies and technological advancements in spirometry devices contribute to the market's growth. Furthermore, a high prevalence of respiratory diseases and a proactive approach to healthcare innovation in North America position the region as a key market leader, with a significant share in the adoption and implementation of spirometry solutions.
Asia Pacific is poised to register robust growth in the spirometers market owing to the region's rising prevalence of respiratory disorders coupled with a growing geriatric population. Additionally, increasing healthcare expenditure, improving healthcare infrastructure and a surge in awareness regarding respiratory health further drive the market. Moreover, technological advancements, the adoption of portable and affordable spirometry devices and the expansion of healthcare access to rural areas foster the market's growth in the Asia Pacific region.
Some of the key players in spirometers market include Benson Medical Instruments, Bionet America, Inc., CareFusion, Cosmed Srl, Fukuda Sangyo Co., Ltd., Future Med Devices Pvt. Ltd., Medikro Oy, MGC Diagnostics Corporation, Midmark Corporation, Morgan Scientific Inc., NDD Medical Technologies, Nihon Kohden Corporation, Schiller AG, SDI Diagnostics, Vitalograph Ltd and Welch Allyn, Inc.
In September 2023, Alveofit (Roundworks Technologies) has received approval from the US Food and Drug Administration (FDA) for its portable digital spirometer, alveoair. With this approval, the company plans to start distributing the product in the US.
In January 2023, Koneksa, a healthcare technology company developing evidence-based validated digital biomarkers, today announced the launch of a clinical study comparing the treatment effect between at-home mobile spirometry using digital biomarkers and in-clinic spirometry in patients with moderate asthma on long-acting beta-agonist (LABA) treatment.
In September 2022, RxCap, Inc. collaborated with ZEPHYRx to connect the ZEPHYRx online spirometry platform to RxCap's remote surveillance platform. RxCap's corporate customers, who include providers and payers, may now track the lung health of their clients and patients who have severe respiratory diseases.